Analysts Have Conflicting Sentiments on These Healthcare Companies: Intercept Pharma (NASDAQ: ICPT), Becton Dickinson (NYSE: BDX) and Xeris Pharmaceuticals Inc (NASDAQ: XERS)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intercept Pharma (ICPTResearch Report), Becton Dickinson (BDXResearch Report) and Xeris Pharmaceuticals Inc (XERSResearch Report).

Intercept Pharma (ICPT)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Intercept Pharma, with a price target of $135. The company’s shares opened today at $62, close to its 52-week low of $58.21.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.5% and a 48.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Alder Biopharmaceuticals, and Karyopharm Therapeutics.

Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $151.44, implying a 144.3% upside from current levels. In a report issued on July 23, Raymond James also maintained a Buy rating on the stock with a $165 price target.

See today’s analyst top recommended stocks >>

Becton Dickinson (BDX)

RBC Capital analyst Brandon Henry maintained a Hold rating on Becton Dickinson on August 6 and set a price target of $248. The company’s shares opened today at $246.53.

According to TipRanks.com, Henry is a 4-star analyst with an average return of 9.1% and a 68.6% success rate. Henry covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Edwards Lifesciences, and Integra Lifesciences.

Becton Dickinson has an analyst consensus of Strong Buy, with a price target consensus of $276.

Xeris Pharmaceuticals Inc (XERS)

RBC Capital analyst Randall Stanicky maintained a Buy rating on Xeris Pharmaceuticals Inc yesterday and set a price target of $18. The company’s shares opened today at $10.03, close to its 52-week low of $6.85.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -18.9% and a 22.6% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Osmotica Pharmaceuticals Plc, and Amneal Pharmaceuticals Inc.

Currently, the analyst consensus on Xeris Pharmaceuticals Inc is a Moderate Buy with an average price target of $27, a 169.2% upside from current levels. In a report issued on July 25, Mizuho Securities also maintained a Buy rating on the stock with a $27 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.